13 August 2021
RUA Life Sciences plc
("RUA" or the "Company")
2021 Notice of Annual General Meeting - Correction
RUA Life Sciences (AIM:RUA) , the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), announces that resolution numbered 7 ("Resolution 7") set out in its Notice of 2021 Annual General Meeting (the "Notice") to be held on Tuesday 31 August 2021 ("AGM") contained certain typographical errors. Resolution 7 refers to proposed authorities to allot (or grant rights over) new ordinary shares in the capital of RUA pursuant to either an open offer or a rights issue. As set out in the explanatory notes to the Notice, the intention is that such authorities comply with the Investment Association's guidelines and be limited to an aggregate nominal value equal to (i) approximately 33% with regard to paragraph 7.1 of Resolution 7, and (ii) approximately 66% in relation to paragraph 7.2 of Resolution 7.
Accordingly, the maximum number of new ordinary shares which may be allotted pursuant to (a) paragraph 7.1 should be equal to an aggregate nominal value of £369,746 (not £396,746 as currently stated), and (b) paragraph 7.2 should be equal to an aggregate nominal value of £739,492 (not £793,492 as currently stated). A procedural resolution to approve such corrected Resolution 7 will be proposed at the AGM. A copy of the corrected Notice is available to view in the "Investor Relations" section of RUA's website at https://rualifesciences.com/investor-relations/. The corrected Notice is also available for inspection at RUA's registered office (c/o Davidson Chalmers Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ, UK). As these were clerical errors, no new Notice is required to be sent out to shareholders.
If shareholders have any questions in connection with the proposed business of the AGM, or the contents of this communication, they should email RUA's Company Secretary , Kate Full, at Kate.Full@rualifesciences.com.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
Shore Capital (Nominated Adviser and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0)20 7408 4080
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon TM , the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-Eon TM , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
| RUA Medical : | End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist. |
| RUA Biomaterials : | Licensor of Elast-Eon TM polymers to the medical device industry. |
| RUA Vascular: | Development of large bore polymer sealed grafts and soft tissue patches. |
| RUA Structural Heart : | Development of tri leaflet polymeric heart valves. |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
